Log In
Print
BCIQ
Print
Print this Print this
 

asunaprevir/daclatasvir/BMS-791325 (asunaprevir/daclatasvir/beclabuvir)

  Manage Alerts
Collapse Summary General Information
Company Bristol-Myers Squibb Co.
DescriptionFixed-dose oral combination of asunaprevir, an HCV NS3 protease inhibitor; daclatasvir, a selective HCV NS5A protein inhibitor; and beclabuvir (BMS-791325), a non-nucleoside HCV NS5B polymerase inhibitor
Molecular Target HCV NS3 protease ; HCV NS5A protein
Mechanism of ActionViral polymerase inhibitor; Viral protease inhibitor; HCV non-structural protein 5A inhibitor
Therapeutic ModalitySmall molecule: Combination
Latest Stage of DevelopmentPhase III
Standard IndicationHepatitis C virus (HCV)
Indication DetailsTreat chronic HCV infection
Regulatory Designation

U.S. - Breakthrough Therapy (Treat chronic HCV infection)

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today